Cegedim

Legacy Challenges Will Test Healthcare Digitalization As Modest Opportunities Open

AnalystLowTarget

Not Invested

Consensus Narrative from 3 Analysts

Published

18 Jul 25

AnalystLowTarget's Fair Value

€11.00

5.5% undervalued

04 Sep

€10.40

-17.5%

-1.9%

-17.5%

-1.9%

Edit anytime before Jul 18 10:14 PM. Then post Updates to your followers.

Author's Valuation

€11.0

5.5% undervalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

€11.0

5.5% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

3.23%

Healthtech revenue growth rate

4.84%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

12.10%

Calculation

€28.77m

Earnings '28

7.39x

PE Ratio '28

€212.51m

Market Cap '28

€212.51m

Market Cap '28

13.71m

No. shares '28

€15.50

Share Price '28

€15.50 Share Price '28

Discounted to 2025 @ 12.10% p.a.

€11.00

Fair Value '25